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Epidemiology and Natural History of Primary Biliary
Cholangitis in the Chinese: A Territory-Based Study
in Hong Kong between 2000 and 2015
Ka-Shing Cheung, MBBS, MPH1, Wai-Kay Seto, MD1,2, James Fung, MD1,2, Ching-Lung Lai, MD1,2 and Man-Fung Yuen, MD, PhD1,2
OBJECTIVES: Studies on the epidemiology of primary biliary cholangitis (PBC) in the Chinese population are lacking. We aimed to
determine the epidemiology of PBC in Hong Kong (HK) with a population of 7.3 million.
METHODS: We retrieved data from the electronic database of the HK Hospital Authority, the only public healthcare provider in
Hong Kong. PBC cases between 2000 and 2015 were identified by International Classification of Diseases (ICD)-9 code. We
estimated the age-/sex-adjusted incidence rate and prevalence of PBC, and analyzed the adverse outcomes (hepatocellular
carcinoma (HCC), liver transplantation, and death).
RESULTS: One thousand and sixteen PBC patients aged ≥ 20 years were identified (female-to-male ratio 4:1; median age 60.6
years, interquartile range (IQR) 51.8–72.6 years; median follow-up 5.6 years, IQR 1.6–8.7 years). The average age/sex-adjusted
annual incidence rate and prevalence were 8.4 per million person-years and 56.4 per million, respectively. Between 2000 and 2015,
the age/sex-adjusted annual incidence rate increased from 6.7 to 8.1 per million person-years (Poisson P= 0.002), while age/sex-
adjusted prevalence increased from 31.1 to 82.3 per million (Poisson Po0.001). Fifty patients developed HCC, and 49 underwent
liver transplantation. Case fatality risk decreased from 10.8 to 6.4% (Poisson P= 0.003). The 5- and 10-year overall survival rates
were 81.5 and 78.3%, whereas the transplant-free survival rates were 78.0% and 74.3%, respectively. Increasing age, cirrhosis and
being treatment-naïve were associated with lower transplant-free survival.
CONCLUSIONS: There is a considerable increase in the incidence and prevalence of PBC in the Chinese population over the
past 16 years, with significant morbidity and mortality.
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic liver
disease due to immune-mediated attack on the small-sized
biliary ducts leading to progressive ductal destruction and loss.1
It is typically characterized by the presence of anti-mitochondrial
antibodies (AMA) serologically. The major complications
include cirrhosis leading to hepatic decompensation as well
as hepatocellular carcinoma (HCC).1 Recently, a change of
terminology, from primary biliary cirrhosis to primary biliary
cholangitis, has been advocated to reflect more accurately the
natural history and characteristics of this disease.2
The epidemiology of PBC has been well described in the
western population, with incidence rate and prevalence
ranging from 3.3 to 58 per million person-years and 19 to
402 per million, respectively.3 PBC is most prevalent in North
America and northern Europe, especially in the Scandinavian
regions and Britain.4 The disease prevalence has been
increasing in the West, which could be attributed to several
factors: improved survival with ursodeoxycholic acid (UDCA),
increased disease awareness, advances in diagnosis, and
better retrieval of data by electronic medical systems.5
However, population-based studies are lacking in the Asian
countries including China,3 except South Korea, in which the
age-/sex-adjusted incidence rate and prevalence were esti-
mated to be 8.6 per million person-years and 47.5 per million,
respectively.6 Epidemiological data are important to ascertain
the disease burden, to help in resource planning, and to
provide basis for further researches regarding disease etio-
logy such as genetic and environmental factors.
The aim of the present study was to determine the
epidemiology of PBC in Hong Kong. Adverse outcomes
including HCC, need of liver transplantation, and death would
also be investigated.
METHODS
Data sources and study population. Data were retrieved
from the Clinical Data Analysis and Reporting System
(CDARS) and the Clinical Management System (CMS) of
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the Hong Kong Hospital Authority. The Hospital Authority is
the only public healthcare provider which covers 87–94%
of all secondary and tertiary care in Hong Kong with a
population of around 7.3 million.7 In 2012, the outpatient
attendances reached 6.88 million persons. Under this
healthcare system, there are altogether 42 public hospitals
and institutions, 47 Specialist Outpatient Clinics, and 73
General Outpatient Clinics.8 Essential clinical data including
demographics, date of hospitalizations and consultations,
diagnoses, investigation results, management (both proce-
dures and medications), and mortality are recorded electro-
nically in the CMS for easy access to patient data to facilitate
daily clinical practice of physicians.9 Data in the CMS are also
transferred to the CDARS for both administrative and
research purposes. A number of high-quality, population-
based studies have been conducted based on the data
retrieved from CDARS.10–14 Local studies showed that the
coding system in CDARS was accurate with high positive and
negative predictive values of more than 90%.12,15
In the present study, no personal identifiable data were
retrieved from the database system. The study protocol was
approved by the Institutional Review Board, The University
of Hong Kong and West Cluster of Hospital Authority,
Hong Kong.
Case ascertainment. The study period ranged from year
2000 to year 2015. PBC cases with age ≥ 20 years between
1999 and 2015 were identified from CDARS with the
International Classification of Diseases (ICD)-9 code of
571.6. PBC cases in 1999 were also identified so that the
number of new cases in 2000 could be determined.
Demographics of these cases (including age at diagnosis,
gender, date of diagnosis, and date of death) were obtained.
Cases with HCC, cirrhosis, and cirrhotic complications
including esophageal varices, gastric varices, ascites, portal
hypertension, hepatic encephalopathy, and hepatorenal syn-
drome were identified with the ICD-9 codes as shown in
Supplementary Table 1.
These epidemiological data allowed the calculation of age-
and sex-adjusted incidence rate and prevalence of PBC.
Adverse outcomes including HCC, need of liver transplanta-
tion, and death were also analyzed.
Data validation. To validate the coding accuracy, we
reviewed the medical records from both the CMS and case
notes of the patients from the Hong Kong West (HKW)
cluster, which is one of the seven hospital clusters of the
Hospital Authority. Queen Mary Hospital is the only acute
hospital in the HKW cluster, and is also a tertiary referral
center which provides liver transplantation services.
PBC was diagnosed in our unit if two out of the three criteria
were fulfilled: (1) cholestatic liver function pattern with alkaline
phosphatase (ALP) raised to at least 1.5 times the upper limit
of normal; (2) presence of anti-mitochondrial antibody (AMA);
(3) histology showing “nonsuppurative destructive cholangitis
with destruction of interlobular biliary ducts”.16
Positive predictive value (PPV) was calculated by dividing
the number of patients who truely have PBC by the number of
patients identified to have PBC by the CDARS (n= 276). To
calculate the negative predictive value (NPV), we randomly
sampled 276 patients from a group of non-PBC patients
identified by the CDARS (92 patients for each of the three
periods: 2000–2005, 2006–2010, and 2011–2015), and cross
validated with the records of PBC patients who followed up
in our hepatology unit. The validity of the coding over the
periods of 2000–2005, 2006–2010, and 2011–2015 were also
assessed.
Statistical analyses. All statistical analyses were performed
using R version 3.2.3 (A language and environment for
statistical computing, Vienna, Austria, ISBN 3-900051-07-0,
URL http://www.R-project.org) statistical software. Continu-
ous variables were expressed as median and interquartile
range (IQR). Mann–Whitney U-test was used to compare
continuous variables between two groups. The χ2-test or
Fisher’s exact test when appropriate, was applied for compar-
ing categorical variables. The incidence rate and prevalence
of PBC between 2000 and 2015 were calculated. These two
estimates were age/sex-adjusted to the population of Hong
Kong in year 2000.17 Evaluation of the count data and
temporal trends was assessed by Poisson regression model.
The Cox proportional hazards model was used to identify
variables that were associated with adverse outcomes. The
Kaplan-Meier method was used to analyze the adverse
outcomes, and statistical significance was determined by
means of log-rank test. A P-value ofo0.05 was used to define
statistical significance.
RESULTS
Data validation. Between 2000 and 2015, a total of 1,016
PBC patients aged at least 20 years were identified. Among
them, 276 patients (27.2%) were from the HKW cluster. Of
these, 240 were confirmed to have PBC after cross validating
with the medical records, yielding a PPV of 87%. None was
found to have PBC from a random sample of non-PBC
patients identified by CDARS (n=276), yielding a NPV of
100%. Between 2000 and 2005, 118 PBC cases out of 127
(93%) were correctly coded. Between 2006 and 2010, the
coding was correct for 77 PBC cases out of 95 (81%).
Between 2011 and 2015, 45 PBC cases out of 54 were rightly
coded (83%).
Patient characteristics. Of the 1,016 PBC patients identi-
fied, 79% of cases being female (female cases 802; male
cases 214). Among these cases, 892 were newly diagnosed
(female cases 704; male cases 188). The median duration of
follow-up was 5.6 years (interquartile range (IQR) 1.6–8.7
years). The median age at diagnosis was 60.6 years (IQR
51.8–72.6 years). Women were diagnosed with PBC earlier
than men. The median age at diagnosis was 59.8 years (IQR
51.4–71.8 years) for women, compared with 65.2 years (IQR
54.6–75.2 years) for men (P= 0.008). The proportion of
patients with cirrhosis did not change significantly between
2000 and 2015 (29.1% in 2000 and 24.1% in 2015; Poisson
P= 0.456; Table 1a). The proportion of patients receiving
UCDA increased from 68.4 to 86.0% between 2000 and 2015
(Poisson Po0.001; Table 1b).
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Incidence rate and prevalence. The crude incidence rate of
PBC in 2015 was 8.9 per million person-years.
The average age-/sex-adjusted annual incidence rate of
PBC was 8.4 per million person-years between 2000 and
2015. Age-/sex-adjusted annual incidence rate of PBC
increased from 6.7 to 8.1 per million person-years between
2000 and 2015 (Poisson P= 0.002; Figure 1a).
Increasing age was associated with increasing incidence of
PBC (Table 2a). For women, the average annual incidence
rate was highest among 60- to 79-year-old patients (33.6 per
million person-years), compared with the youngest age group
(20–39 years) (1.1 per million person-years). For men, the
average annual incidence rate was highest among patients
aged 80 years or above (15.7 per million person-years),
compared with the youngest age group (0.8 per million
person-years). The incidence rate was also dependent on
gender, with PBC more frequently to be diagnosed in women.
The age-adjusted incidence rate was 12.8 per million person-
years in women compared with 3.8 per million person-years
in men.
The average age-/sex-adjusted prevalence was 56.4 per
million. Age-/sex-adjusted prevalence of PBC increased from
31.1 per million to 82.3 per million between 2000 and 2015
(Poisson Po0.001; Figure 1b).
In 2015, the crude prevalence of PBC was 109.0 per million
in the entire population (Table 2b). PBC was most prevalent
among 60- to 79-year-old patients (300.2 per million compared
with 10.9 per million among patients aged 20–39 years;
prevalence ratio of 27.5; 95% confidence interval (CI) 18.1–
41.9). The prevalence of PBC was higher among women, with
a female to male ratio of 6.3 (238.2 per million vs. 37.8 per
million).
Adverse outcomes. The development of various adverse
outcomes including HCC, need of liver transplantation and
death was investigated.
There were 50 newly diagnosed HCC cases (4.9% of total
PBC cases; 21 women and 29 men). A higher proportion of
men developed HCC than women (13.6 vs. 2.6%; Po0.001).
The 5- and 10-year probabilities of HCC were 1.5% (95% CI
0.6–2.3%) and 2.8% (95%CI 1.2–4.4%), respectively. Overall,
the median age at diagnosis was 73.6 years (IQR 62.1–81.5
years), without significant difference betweenwomen andmen
Table 1a Cirrhosis in PBC patients between 2000 and 2015
Year (no. of cases) 2000 (n= 158) 2001 (n= 178) 2002 (n= 209) 2003 (n= 226) 2004 (n= 252) 2005 (n= 269) 2006 (n= 288) 2007 (n= 317)
No. of patients with
cirrhosis
46 (29.1%) 50 (28.1%) 53 (25.4%) 57 (25.2%) 60 (23.8%) 63 (23.4%) 68 (23.6%) 78 (24.6%)
Year (no. of cases) 2008 (n= 358) 2009 (n= 421) 2010 (n= 501) 2011 (n= 530) 2012 (n= 560) 2013 (n= 584) 2014 (n= 625) 2015 (n= 656)
No. of patients with
cirrhosis
86 (24.0%) 110 (26.1%) 121 (24.2%) 126 (23.8%) 134 (23.9%) 151 (25.9%) 152 (24.3%) 158 (24.1%)
PBC, primary biliary cholangitis.
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Figure 1 (a) Annual age-/sex-adjusted incidence rate of PBC between 2000 and
2015. (b) Annual age-/sex-adjusted prevalence of PBC between 2000 and 2015.
PBC, primary biliary cholangitis.
Table 1b UCDA use in PBC patients between 2000 and 2015
Year (no. of cases) 2000 (n= 158) 2001 (n= 178) 2002 (n= 209) 2003 (n= 226) 2004 (n=252) 2005 (n= 269) 2006 (n= 288) 2007 (n= 317)
No. of patients receiving UDCA 108 (68.4%) 131 (73.6%) 152 (72.7%) 160 (70.8%) 187 (74.2%) 205 (76.2%) 210 (72.9%) 225 (71.0%)
Year (no. of cases) 2008 (n= 358) 2009 (n= 421) 2010 (n= 501) 2011 (n= 530) 2012 (n=560) 2013 (n= 584) 2014 (n= 625) 2015 (n= 656)
No. of patients receiving UDCA 267 (74.6%) 331 (78.6%) 404 (80.6%) 436 (82.3%) 463 (82.7%) 475 (81.3%) 531 (85.0%) 564 (86.0%)
PBC, primary biliary cholangitis; UCDA, ursodeoxycholic acid.
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(73.5 years (IQR 61.2–81.2 years) and 74.7 years (IQR 62.8–
81.6 years), respectively; P= 0.783). There was one HCC
case in the 20- to 39-year age group, seven cases in the 40- to
59-year age group, 25 cases in the 60- to 79-year age group,
and 17 cases in those aged 80 years or above. Thirty-four
patients with HCC died between 2000 and 2015. Eleven out of
21 women (52.4%) and 23 out of 29 men (79.3%) died. The
median age at death was 78.6 years (IQR 66.9–83.3 years),
without significant difference between women and men (80.8
years (IQR 75.6–87.2 years) and 76.3 years (IQR 65.2–81.8
years), respectively; P= 0.146).
Liver transplantation was performed in 49 patients (4.8% of
total PBC cases). Forty out of 802 were women (5.0%)
and nine out of 214 were men (4.4%). The 5- and 10-year
probabilities of transplantation were 4.6% (95% CI 3.0–6.2%)
and 5.3% (95%CI 3.5–7.0%), respectively. The median age at
liver transplantation was 54.0 years (IQR 48.4–60.7 years).
Among those aged less than 40 years, none received
transplantation. There were 34 liver transplantation cases
in the 40- to 50-year age group, and 15 cases in the 60- to
79-year age group.
Four hundred and two PBC patients died between 2000
and 2015 (female cases 277,male cases 125). Themedian life
expectancy was 72.4 years (IQR 61.4–81.2 years), without
significant difference between women and men (72.5 years
(IQR 61.7–82.0 years) and 71.6 years (IQR 59.1–79.5 years),
respectively; P=0.217). The annual case fatality risk
decreased from 10.8 to 6.4% between 2000 and 2015
(Poisson P= 0.003; Table 3).
Overall, the 5- and 10-year survival rates were 81.5%
(95% CI 78.8–84.3%) and 78.3% (95% CI 75.1–81.6%),
respectively (Figure 2). By multivariate analysis, older age at
diagnosis (hazards ratio (HR) 1.03; 95% CI 1.01–1.04) as well
as presence of cirrhosis (HR 1.60; 95% CI 1.13–2.26) were
significant risk factors, and UCDA prescription at diagnosis
was a protective factor (HR 0.42; 95% CI 0.30–0.58), while
gender did have statistical significance (HR for male gender:
1.24; 95% CI 0.87–1.76; Table 4).
Overall, the 5- and 10-year transplant-free survival
rates were 78.0% (95% CI 75.1–80.9%) and 74.3% (95% CI
71.1–77.7%), respectively (Figure 3a). By multivariate
analysis, older age at diagnosis (HR 1.01; 95% CI 1.0002–
1.02) as well as presence of cirrhosis (HR 2.05; 95% CI
1.51–2.80) were significant risk factors, and UCDA prescrip-
tion at PBC diagnosiswas a protective factor (HR 0.57; 95%CI
0.42–0.76), while gender did not have statistical significance
Table 3 Case fatality risk (%) of PBC cases in Hong Kong between 2000 and 2015
Year (no. of cases) 2000 (n= 158) 2001 (n= 178) 2002 (n= 209) 2003 (n= 226) 2004 (n= 252) 2005 (n= 269) 2006 (n= 288) 2007 (n= 317)
Annual number of deaths (case fatality risk, %)
Female 9 (7.3%) 8 (5.4%) 18 (10.4%) 14 (7.4%) 17 (8.3%) 7 (3.3%) 11 (4.6%) 20 (7.7%)
Male 8 (22.9%) 5 (15.6%) 3 (8.3%) 2 (5.3%) 7 (14.3%) 9 (16.7%) 7 (13.7%) 6 (10.5%)
Total 17 (10.8%) 13 (7.3%) 21 (10.0%) 16 (7.1%) 24 (9.5%) 16 (5.9%) 18 (6.3%) 26 (8.2%)
Year (no. of cases) 2008 (n= 358) 2009 (n= 421) 2010 (n= 501) 2011 (n= 530) 2012 (n= 560) 2013 (n= 584) 2014 (n= 625) 2015 (n= 656)
Annual number of deaths (case fatality risk, %)
Female 11 (3.8%) 19 (5.6%) 22 (5.4%) 19 (4.4%) 24 (5.1%) 22 (4.5%) 26 (4.9%) 30 (5.4%)
Male 6 (9.2%) 12 (15.2%) 10 (10.9%) 14 (14.7%) 7 (7.9%) 9 (9.8%) 8 (8.3%) 12 (12%)
Total 17 (4.7%) 31 (7.4%) 32 (6.4%) 33 (6.2%) 31 (5.5%) 31 (5.3%) 34 (5.4%) 42 (6.4%)
PBC, primary biliary cholangitis.
Figure 2 Kaplan–Meier survival plot for overall survival.
Table 2a Average age/sex-adjusted annual Incidence rate of PBC (per million
person-years) according to age and gender between 2000 and 2015
Age (years) Women Men Total Incidence rate ratio (95% CI)
20–39 1.1 0.8 2.1 Reference
40–59 17.1 3.4 10.1 4.82 (3.39–6.86)
60–79 33.6 10.7 22.2 10.61 (7.47–15.09)
≥80 31.5 15.7 25.9 12.40 (8.12–18.92)
Overall 12.8 3.8 8.4 —
CI, confidence interval; PBC, primary biliary cholangitis.
Table 2b Crude prevalence of PBC (per million population) according to age
and gender in 2015
Age (years) Women Men Total Incidence rate
ratio (95% CI)
20–39 75.3 8.8 10.9 Reference
40–59 148.3 23.9 92.2 8.45 (5.50–13.0)
60–79 508.5 89.3 300.2 27.50 (18.06–41.90)
≥80 353.2 108.6 257.7 23.60 (14.89–37.41)
Overall 238.2 37.8 109.0 —
CI, confidence interval; PBC, primary biliary cholangitis.
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(HR for male gender: 1.23; 95% CI 0.89–1.70) (Table 4).
Figure 3b,c illustrate the comparison of transplant-free survival
of patients according to their baseline cirrhosis and treatment
status, respectively. Transplant-free survival rates were signifi-
cantly higher in patients without cirrhosis (log-rank Po0.001)
and in those who received UCDA (log-rank Po0.001).
DISCUSSION
The epidemiology of PBC has been well reported in the
western countries, but not in the Asian population.3
Population-based studies investigating the epidemiology and
natural history of PBC in the Asian population including the
Chinese are lacking.
Previous studies usually recruited patients from a single
hospital or tertiary referral centers,18–22 except for one
performed in South Korea.6 The present territory-based study
described the epidemiology and natural history of PBC in a
well defined Chinese population.
The strength of this study is its population-based nature, in
which the administrative electronic database system ensures
complete capture of all PBCcases being followed up in the public
healthcare setting. The inherent selection bias in studies
conducted by a few hospitals or tertiary referral centers was
minimized. Case ascertainment was based on ICD-9 coding,
which has been shown to have high PPV and NPVof more than
90% from local studies.12,15 These highly accurate rates were
also confirmed in the present study on PBC that the PPV and
NPV were 87% and 100%, respectively. Therefore, the numera-
tors and denominators could be accurately defined in a Chinese
population with a clearly defined geographic demarcation.
Studies from theWest estimated an incidence rate of 3.3–58
per million person-years and prevalence of 19–402 per
million.3 The estimates from our study were on the lower end
of these ranges, with the average age-/sex-adjusted incidence
rate being 8.4 per million person-years, and the age/
sex-adjusted prevalence 56.4 per million. These data were
consistent with the estimates reported in South Korea (8.6 per
million person-years and 47.5 per million, respectively).6 More
population-based studies are warranted to confirm whether
PBC is less prevalent in the Asian population. Importantly, this
could provide more insights into the genetic and environ-
mental risk factors involved in the pathogenesis of PBC.
From the current study, the incidence rate and prevalence of
PBC in Hong Kong had been increasing. The increase in the
annual incidence rate could be related to increase in disease
awareness, better diagnostic tests (e.g., more sensitive assays
to detect AMA),23 and better diagnosis entry into the electronic
database. In year 2009 and 2010, there was an upsurge in
the incidence of PBC cases (Figure 1a), probably related to
an intensive publicity of PBC in the media in Hong Kong in
February 2009. As a result, there was an enhanced awareness
of diagnosing and reporting this disease in 2009 and 2010. The
overall increase in the prevalence could be attributed to an
increase in the incidence and improved survival with UCDA
(proportion of patients being prescribed with UCDA increased
from 68.4 to 86.0% between 2000 and 2015).
The survival of patients with PBC was similar between the
western and our Chinese cohorts. The 5- and 10-year survival
rates were estimated to be 82 and 78%, respectively in our
study, which were similar to the western population (survival
rates were 88 and 77% at 5 years and 10 years, respec-
tively).24 However the median life expectancy of patients with
PBC in our cohort was only 71.5 years, which was much
shorter than that of the general population in Hong Kong (81.2
years for men and 87.3 years for women in 2015).25
Our study also showed that PBC patients carried significant
liver-related morbidity, with 4.8% developing HCC and 4.9%
requiring liver transplantation. Notably, there were modifiable
factors that could potentially influence transplant-free survival:
older age at diagnosis (HR 1.01), presence of cirrhosis on
diagnosis (HR 2.05) and UCDA prescription (HR 0.57). This
underscores the importance of early diagnosis and prompt
commencement of treatment. It has been recommended that
all PBC patients with deranged liver function test should
be treated with UCDA, regardless of disease stages.16
Classically, PBC is considered to affect patients aged
between 30 and 65 years.26 A meta-analysis including 4,845
patients in the western population showed that the mean age
at diagnosis was 54.5±12 years.24 However, several studies
from other Asian countries outside of Hong Kong (including
Taiwan, Singapore, and South Korea) showed that patients
tended to be diagnosedwith PBCat an older age, ranging from
55.6 to 57.4 years.6,20,21 Our study showed that the median
age at diagnosis was 60.6 years. This estimate was very close
to that reported from a retrospective study conducted by a
local hospital from Hong Kong, which showed the median age
at diagnosiswas 59 years.18 In term of prevalence, we showed
that PBC was commonest among patients aged 60–79 years,
which was consistent with findings from other Asian studies.5,6
Similar to other autoimmune diseases, we showed that PBC
predominantly affected women (79%). Previous studies also
revealed a female preponderance (77–87%) in Asian patients
with PBC.6,20,22
There are a few limitations of our study. First, although the
Hospital Authority is the only public healthcare provider, a
small proportion of secondary and tertiary care was not
covered (around 5–10%).7 Patients who were initially treated
in private hospitals may be missed. As a result, it is possible
that the incidence rate and prevalence of PBC were slightly
underestimated. However, it is not uncommon that these
Table 4 HRs and 95% CIs for the association between different covariates and
(A) overall survival, (B) transplant-free survival
Univariate
analysis
95% CI Multivariate
analysis
95% CI
A. Overall survival
aAge 1.03 1.02–1.05 1.03 1.01–1.04
Male sex 1.63 1.15–2.29 1.24 0.87–1.76
Cirrhosis 2.30 1.65–3.20 1.60 1.13–2.26
UCDA 0.35 0.26–0.48 0.42 0.30–0.58
B. Transplant-free survival
aAge 1.02 1.01–1.03 1.01 1.0002–1.02
Male sex 1.58 1.16–2.16 1.23 0.89–1.70
Cirrhosis 2.56 1.91–3.43 2.05 1.51–2.80
UCDA 0.47 0.35–0.62 0.57 0.42–0.76
95% CI, 95% confidence interval; HR, hazards ratio; UCDA, ursodeoxycholic
acid.
aAge was treated as continuous variable in analysis.
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patients will attend public hospitals or clinics later for follow-up
because of the long-term disease monitoring or consultation
for other medical problems, and therefore these PBC cases
will still be captured in the public healthcare database system
in the end. Second, the ICD-9 code of 571.6 encompasses
both PBC and secondary biliary cirrhosis, and therefore the
number of true PBC cases would be less than observed. To
address this concern, we checked the coding validity by cross
checking with patients from our hospital, and found that the
PPV and NPV were 87 and 100% respectively. However,
because of restricted access right, only the medical records in
the CMS from our hospital cluster could be accessed for
coding validation. Biases may arise from differences in coding
practices across different clusters. Nevertheless, as the
clinical data in CMS and CDARS are for clinical management
purposes instead of reimbursement or insurance, there exist no
financial rewards or initiatives. As such, the coding validity is
likely to be consistent across different hospital clusters under
the same management of structure of the Hospital Authority.
Third, information regarding biochemical response to UCDA
could not be retrieved, which may potentially underestimate the
protective effect of UCDA in patients who are treatment-
responsive. Fourth, data on concomitant viral hepatitis infection
(e.g., chronic hepatitis B) were not available.
To address these limitations, future collaboration with all
hepatology units from other hospitals (either public or private
hospitals) in Hong Kong as well as prospective, multi-center
studies with larger sample size can be carried out to ascertain
the epidemiological link of risk factors for developing PBC in
Chinese patients.
In summary, we described the epidemiology of PBC in awell
defined Chinese population and identified factors associated
Figure 3 (a) Kaplan–Meier survival plot for overall transplant-free survival. (b) Kaplan–Meier survival plot for transplant-free survival stratified according to baseline cirrhosis
status. (c) Kaplan–Meier survival plot for transplant-free survival stratified according to baseline treatment status. UCDA, ursodeoxycholic acid.
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with transplant-free survival. There was a considerable
increase in both the incidence and prevalence of PBC in
Hong Kong, which was associated with significant morbidity
andmortality. Early diagnosiswith prompt treatment improving
disease outcome could potentially reduce the disease burden.
CONFLICT OF INTEREST
Guarantor of the article: Ka-Shing Cheung, MBBS and
Man-Fung Yuen, MD, PhD.
Authors contributions: Drs Ka-Shing Cheung and Wai-Kay
Seto were involved with study concept and design; acquisition
of data; analysis and interpretation of data; drafting of
manuscript; Dr James Fung was involved with analysis and
interpretation of data; and critical revision of the manuscript for
important intellectual content. Professors Ching-Lung Lai and
Man-Fung Yuen were involved with the study concept and
design; analysis and interpretation of data; drafting of
manuscript; critical revision of the manuscript for important
intellectual content; and study supervision. The corresponding
authors had full access to all data, and were fully responsible
for the data integrity and statistical analysis. All authors
revised the manuscript and approved the final version of this
article.
Conflict of Interest:WKSeto is an advisory board member of
Bristol-Myers Squibb and Gilead Sciences, and received
speaker fees from Bristol-Myers Squibb, Gilead Sciences and
Novartis. J Fung received research funding from Novartis. CL
Lai received speaker fees and is an advisory board member of
Bristol-Myers and Gilead Sciences. MF Yuen received
speaker fees and research funding and is an advisory board
member of Bristol-Myers Squibb, Novartis, Gilead Sciences
and Roche Diagnostics. The remaining authors declare no
conflict of interest.
Funding source: None.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ The epidemiology of primary biliary cholangitis (PBC) iswell
described in the western population.
✓ Epidemiological studies on prognostic factors associated
with long-term survival in PBC patients are lacking in the
Chinese population.
WHAT IS NEW HERE
✓ There is a considerable increase in the incidence and
prevalence of PBC in the Chinese population between 2000
and 2015.
✓ PBCwas associated with significant morbidity and mortality
in the Chinese.
✓ Increasing age, cirrhosis and being treatment-naïve were
associated with lower transplant-free survival.
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